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BACKGROUND AND OBJECTIVE

DESIGN AND METHODS

RESULTS

Chronic obstructive pulmonary disease (COPD) is the third leading cause of
death in the United States, affecting more than 10 million Americans. Worldwide
COPD is a disease of increasing public health importance as estimates suggest
that COPD will rise from the fourth to the third most common cause of death by
2020.1 Increased exposure to risk factors and an aging population will attribute
to even more patients with COPD.2 Adherence to guideline-recommended
treatment regimens may decrease healthcare costs and improve patient
outcomes.

The Parkview Health institutional review board approved this retrospective chart
review study. Demographic data was collected from the electronic medical
record (EMR) on patients admitted to Parkview Hospital with a primary diagnosis
of COPD exacerbation from March 2017 to March 2018.
Adult patients, 18 years or older, with an admission diagnosis of COPD
exacerbation were included in this study. Patients were excluded if they had
asthma in addition to COPD or were receiving chronic oral steroid treatment at
baseline. Baseline characteristics collected included age, gender, BMI, smoking
history (pack year), current smoking status, COPD medication names, COPD
exacerbation history (number of exacerbation requiring hospitalization in the 12
months prior to index admission), and pneumonia diagnosis within 6 months of
admission.

We evaluated 75 hospitalized patients, of which 23 (30%) were current smokers
upon admission. Maintenance inhaler therapy was deemed appropriate in 20
patients (26.7%) at hospital discharge and in 38 patients (50.7%) within a 3month follow-up period. Therapy was appropriate within a 3-month follow-up
period in 56.9% of patients with a pulmonary consult and in 37.5% of patients
without a pulmonary consult. Among patients who experienced a COPD
exacerbation, 7 of 18 patients (38.9%) were receiving appropriate therapy within
3 months of discharge while 32 of 56 patients (57.1%) without a COPD
exacerbation were receiving appropriate therapy within 3 months.

According to the GOLD guidelines, COPD pharmacotherapy recommendations
are derived from the “ABCD” assessment tool, which takes into consideration a
patient’s symptoms and their history of exacerbations (including prior
hospitalizations). Symptom assessment is completed using either the Modified
British Medical Research Council (mMRC) Questionnaire or the COPD
Assessment Test (CAT). This is a change from the diagnostic criteria outlined in
the 2010 NICE COPD Guidelines which recommend diagnosing stages of COPD
based on stable-state forced expiratory volume in 1 second (FEV1). The 2017
GOLD Guidelines also place dual bronchodilators earlier than inhaled
corticosteroids (ICS) in the stepwise progression of therapy based on symptoms
(COPD assessment tool score) and rates of exacerbations. These changes were
primarily made based on a few breakthrough studies including the FLAME and
LANTERN trials which showed decreased exacerbations, improved quality of life
measures, and decreased rates of pneumonia in patients on dual
bronchodilators compared to LABA/ICS combinations.3 With these recent
changes to the guidelines, it is necessary to evaluate the appropriateness of
treatment regimens for patients with a diagnosis of COPD.
The purpose of this study was to determine how hospitalizations for COPD
exacerbation influence changes to maintenance inhaler therapy and adherence
to practice guideline recommendations.

Baseline Characteristics
Age, median (IQR)
Female, n (%)
Currently Smoke, n (%)
Pack Year History, median (IQR)
Req. Mechanical Ventilation, n (%)
FEV1%, mean (SD)

Baseline Inhaler Use

Total Population (n=75)
68.1 (58.5 – 77.8)
36 (48.0%)
23 (30.7%)
36 (27.8 – 50.0)
7 (9.3%)
46% (14.6%)

LABA/LAMA, n (%)
LABA/ICS, n (%)
LABA/LAMA/ICS, n (%)
No Maintenance Inhaler Use, n (%)

21%
34%

Appropriate therapy

90%

Appropriate Medication at Discharge/Follow-Up

None

LAMA, LAMA+LABA

LAMA

LAMA+LABA

LAMA+LABA

LAMA+LABA+ICS

LABA+ICS

LAMA+LABA+ICS

LAMA+LABA+ICS

LAMA+LABA+ICS (optimized dosing)

A COPD exacerbation in the 6-month follow-up period included any
hospitalization in which the primary diagnosis was COPD exacerbation or any
outpatient receipt of oral corticosteroid therapy for COPD exacerbation. The
time to COPD exacerbation was also collected. Descriptive statistics were used to
describe the appropriateness of therapy at hospital discharge and in the 6month follow-up period.

35.0%

82.76%

25.0%

64.71%

60%

56.90%

50%

20.0%

18.4%

15.0%

40%
30%
20%

30.6%

30.0%

29.41%

25.86%

35.29%

10.0%

10%

5.0%

0%

Pulmonary Consult n=58

Medication Therapy at Hospital Admission

Exacerbation Rate Based on Presence of Appropriate or
Inappropriate Therapy

100%

70%

The primary outcome was the appropriateness of maintenance inhaler therapy
at hospital discharge and at the first follow-up appointment considering
guideline recommendations. The secondary outcome was hospital readmission
rates within 6 months of the initial COPD exacerbation. The following table was
used to define appropriateness:

Appropriate therapy

Appropriateness of Therapy at Discharge & Follow-up
Based on Presence of a Pulmonary Consult

80%

6 (8.0%)
11 (14.7%)
10 (13.3%)
43 (57.3%)

Patients on Appropriate Therapy During Follow-up
Period

Patients on Appropriate Therapy
at Discharge

Appropriate at discharge

No Pulmonary Consult n=17

Appropriate During Follow-up

0.0%

Overall Appropriateness

Appropriate Therapy

Not Appropriate Therapy

DISCUSSION

• Hospitalization for COPD exacerbation may provide opportunities for
pharmacists to help ensure patients receive appropriate therapy.
• Quality transitions of care is needed in this population as they are at a high
risk of readmission.
• Further studies should investigate whether patients with different disease
severity are at different risks for exacerbation based on how therapy is
adjusted following COPD exacerbation
• A larger cohort of patients would be needed to determine if therapy
adjustment around the time of COPD exacerbation is associated with a higher
number of subsequent exacerbations
or
time
to
exacerbation.
CONCLUSION

In patients admitted for a COPD exacerbation, maintenance inhaler therapy is
infrequently modified upon discharge and is modified in less than half of patients
within a 3-month follow-up period. Patients not on appropriate therapy are more
likely to experience another COPD exacerbation within 6 months.
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Y
EXACERBATION
HISTORY
≥2
Or ≥ 1
leading to
hospital
admission

Group C

Group D

LAMA + LABA

LABA + ICS

Consider Roflumilast if
FEV1<50% pred. and patient
has chronic bronchitis
Further
Exacerbation(s)

Further
Exacerbation(s)

LAMA + LABA +
ICS

Persistent
Symptoms/Further
Exacerbation(s)

Further
Exacerbation(s)

LAMA
LAMA

Group A

0 or 1
(not
leading to
hospital
admission

Consider
Macrolide in
former smokers

LAMA + LABA

LAMA +
ICS

Group B

Continue, stop, or
try alternative class
of bronchodilator

LAMA + LABA

Evaluate Effect

A Long Acting
Bronchodilator
LAMA or LABA

Persistent
Symptoms

A Bronchodilator
mMRC 0-1
CAT < 10

X

SYMPTOMS

mMRC ≥ 2
CAT ≥ 10

